Dr Sunit Sarkar

Medical Oncologist
Become a Patient

Dr Sunit Sarkar believes in holistic, patient-centred care. In the evolving oncology landscape, he is committed to utilising the latest approach to treatment and tailoring treatment plans to meet the individual needs of his patients and their loved ones.


Dr Sunit Sarkar is a passionate medical oncologist at Icon Cancer Hobart. In 2010 he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Monash University and spent the early years of his medical training at Box Hill Hospital. Dr Sarkar subsequently completed his specialist medical oncology training at the Royal Hobart Hospital, Box Hill Hospital and Peter MacCallum Cancer Centre, gaining extensive experience in managing a broad range of cancers.

Dr Sarkar is a strong advocate for clinical research and clinical trials in both his private practice and role as medical oncology consultant at Calvary St. John’s Hospital and Royal Hobart Hospital. He is a fellow of the Royal Australasian College of Physicians (FRACP) and recently completed a breast cancer fellowship at Nepean Hospital. His clinical experience covers a broad range of solid tumour malignancies with a special interest in breast cancer, gastrointestinal cancer, lung cancer, melanoma, neuro-oncology and skin cancer.

Affiliations & Memberships

  • Royal Australasian College of Physicians (RACP)
  • Thoracic Oncology Group of Australia (TOGA)

Special Interests

Dr Sunit Sarkar accepts referrals for all cancer types with a special clinical interest in:
  • Brain and spine (CNS) cancer
  • Breast cancer
  • Gastrointestinal cancer
  • Lung cancer
  • Melanoma

Icon Locations

Hobart View centre

Visiting Locations

  • Royal Hobart Hospital
  • Calvary St John’s Hospital


  • A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. S. Sarkar, B. Tran, L. Horvath, M. Lam, P. Savas, P. Grimison, J. Whittle, K. Kuo, N. Signal, D. Edmonds, P. Hogg, D. Rischin, J. Desai & A. Hamilton. Cancer Chemotherapy and Pharmacology, 2021.